B
Bull
Bull · 25%TCRT
$3.93
Szenariopreis
$1.605
-0.053 (-3.31%)Zum Schluss
Loading chart…
- High
- 1.710
- Open
- 1.660
- VWAP
- 1.62
- Vol
- 35.68K
- Mkt Cap
- 11.53M
- Low
- 1.550
- Amount
- 57.86K
- EV/EBITDA, TTM
- 0.00
Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
AI analysis of Alaunos Therapeutics Inc (TCRT)
sellAlaunos Therapeutics Inc is not a good buy right now due to its current price of 1.605, a very low RSI of 16.85 indicating oversold conditions, and a significant year-to-date decline of 51.07%. The company is facing ongoing financial losses, with a reported Q2 loss of $952,000, and a forward P/E ratio of 18.48 suggests overvaluation relative to its earnings potential.
Bewertungskennzahlen
The current forward P/E ratio for Alaunos Therapeutics Inc (TCRT) is 18.48, compared to its 5-year average forward P/E of 0.41.
Alphio AI Price Scenarios for TCRT
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
9.508-14Yahoo FinanceAlaunos Therapeutics Reports Q2 Loss of $952,000
5.006-29NewsfilterAlaunos Announces New Statistical Analysis of ALN1003's Liver Weight Findings
8.505-28NASDAQ.COMQ32 Bio Soars Over 85% on $55 Million Private Placement Announcement
5.005-26stocktwitsAlaunos Therapeutics Reports Progress on Obesity Drug ALN1003
- 8.505-26Newsfilter
ALN1003 Shows Promising Results in Metabolic Disease Models
TCRT FAQ — answered by Alphio AI
Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Alaunos Therapeutics Inc is not a good buy right now due to its current price of 1.605, a very low RSI of 16.85 indicating oversold conditions, and a significant year-to-date decline of 51.07%. The company is facing ongoing financial losses, with a reported Q2 loss of $952,000, and a forward P/E ratio of 18.48 suggests overvaluation relative to its earnings potential.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.